These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 18663089

  • 1. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
    Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP.
    Circulation; 2008 Aug 12; 118(7):722-30. PubMed ID: 18663089
    [Abstract] [Full Text] [Related]

  • 2. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
    Gomez-Puerto MC, van Zuijen I, Huang CJ, Szulcek R, Pan X, van Dinther MA, Kurakula K, Wiesmeijer CC, Goumans MJ, Bogaard HJ, Morrell NW, Rana AA, Ten Dijke P.
    J Pathol; 2019 Nov 12; 249(3):356-367. PubMed ID: 31257577
    [Abstract] [Full Text] [Related]

  • 3. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J, Zhang YY.
    Am J Physiol Heart Circ Physiol; 2008 Aug 12; 295(2):H677-90. PubMed ID: 18552156
    [Abstract] [Full Text] [Related]

  • 4. Physiologic and molecular consequences of endothelial Bmpr2 mutation.
    Majka S, Hagen M, Blackwell T, Harral J, Johnson JA, Gendron R, Paradis H, Crona D, Loyd JE, Nozik-Grayck E, Stenmark KR, West J.
    Respir Res; 2011 Jun 22; 12(1):84. PubMed ID: 21696628
    [Abstract] [Full Text] [Related]

  • 5. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G, Wang X, Li Y, He L.
    Stem Cell Res Ther; 2017 Feb 10; 8(1):34. PubMed ID: 28187784
    [Abstract] [Full Text] [Related]

  • 6. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay É, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S.
    J Am Heart Assoc; 2013 Jan 16; 2(1):e005157. PubMed ID: 23525442
    [Abstract] [Full Text] [Related]

  • 7. SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension.
    Han C, Hong KH, Kim YH, Kim MJ, Song C, Kim MJ, Kim SJ, Raizada MK, Oh SP.
    Hypertension; 2013 May 16; 61(5):1044-52. PubMed ID: 23478097
    [Abstract] [Full Text] [Related]

  • 8. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.
    Wang L, Moonen JR, Cao A, Isobe S, Li CG, Tojais NF, Taylor S, Marciano DP, Chen PI, Gu M, Li D, Harper RL, El-Bizri N, Kim YM, Stankunas K, Rabinovitch M.
    Circ Res; 2023 Mar 03; 132(5):545-564. PubMed ID: 36744494
    [Abstract] [Full Text] [Related]

  • 9. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
    Hautefort A, Mendes-Ferreira P, Sabourin J, Manaud G, Bertero T, Rucker-Martin C, Riou M, Adão R, Manoury B, Lambert M, Boet A, Lecerf F, Domergue V, Brás-Silva C, Gomez AM, Montani D, Girerd B, Humbert M, Antigny F, Perros F.
    Circulation; 2019 Feb 12; 139(7):932-948. PubMed ID: 30586714
    [Abstract] [Full Text] [Related]

  • 10. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
    Feng F, Harper RL, Reynolds PN.
    Respirology; 2016 Apr 12; 21(3):526-32. PubMed ID: 26689975
    [Abstract] [Full Text] [Related]

  • 11. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H, Dewachter C, Belhaj A, Rondelet B, Sakai S, Remmelink M, Vachiery JL, Naeije R, Dewachter L.
    J Heart Lung Transplant; 2015 Mar 12; 34(3):468-78. PubMed ID: 25447587
    [Abstract] [Full Text] [Related]

  • 12. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
    Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J.
    Am J Physiol Lung Cell Mol Physiol; 2012 Mar 01; 302(5):L474-84. PubMed ID: 22180660
    [Abstract] [Full Text] [Related]

  • 13. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF, Cao A, Lai YJ, Wang L, Chen PI, Alcazar MAA, de Jesus Perez VA, Hopper RK, Rhodes CJ, Bill MA, Sakai LY, Rabinovitch M.
    Arterioscler Thromb Vasc Biol; 2017 Aug 01; 37(8):1559-1569. PubMed ID: 28619995
    [Abstract] [Full Text] [Related]

  • 14. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.
    Fessel JP, Flynn CR, Robinson LJ, Penner NL, Gladson S, Kang CJ, Wasserman DH, Hemnes AR, West JD.
    Am J Respir Cell Mol Biol; 2013 Nov 01; 49(5):778-87. PubMed ID: 23742019
    [Abstract] [Full Text] [Related]

  • 15. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
    Orriols M, Gomez-Puerto MC, Ten Dijke P.
    Cell Mol Life Sci; 2017 Aug 01; 74(16):2979-2995. PubMed ID: 28447104
    [Abstract] [Full Text] [Related]

  • 16. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
    Hwangbo C, Lee HW, Kang H, Ju H, Wiley DS, Papangeli I, Han J, Kim JD, Dunworth WP, Hu X, Lee S, El-Hely O, Sofer A, Pak B, Peterson L, Comhair S, Hwang EM, Park JY, Thomas JL, Bautch VL, Erzurum SC, Chun HJ, Jin SW.
    Circulation; 2017 Jun 06; 135(23):2288-2298. PubMed ID: 28356442
    [Abstract] [Full Text] [Related]

  • 17. Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes.
    Miyagawa K, Shi M, Chen PI, Hennigs JK, Zhao Z, Wang M, Li CG, Saito T, Taylor S, Sa S, Cao A, Wang L, Snyder MP, Rabinovitch M.
    Circ Res; 2019 Jan 18; 124(2):211-224. PubMed ID: 30582451
    [Abstract] [Full Text] [Related]

  • 18. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
    Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J.
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov 18; 301(5):L667-74. PubMed ID: 21856816
    [Abstract] [Full Text] [Related]

  • 19. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
    Wang Y, Zhang XH, Wang HL.
    Can J Physiol Pharmacol; 2011 May 18; 89(5):345-54. PubMed ID: 21619414
    [Abstract] [Full Text] [Related]

  • 20. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X, Tan J, Dai Y, Liu Y, Zou J, Sun J, Ye S, Shen C, Fan L, Chen J, Bian JS.
    J Mol Cell Cardiol; 2018 Mar 18; 116():41-56. PubMed ID: 29374556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.